Exclusive worldwide licence and collaboration agreement with Icahn School of Medicine at Mount Sinai, NY

 31st May 2018


Download full announcement


Renalytix AI PLC to develop Artificial Intelligence solutions for early identification and management of kidney disease.


EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that its subsidiary, Renalytix AI PLC, has signed an exclusive license and collaboration agreement with the Icahn School of Medicine at Mount Sinai in New York, USA, (“Mount Sinai”) (the “Agreement”).  


As previously announced at the time of the Company’s most recent results, EKF is in the process of spinning out its solid tumour necrosis factor (“sTNFR”) biomarker technology into Renalytix AI Inc (“Renalytix AI”), a separate entity, registered in the USA. The Directors believe the sTNFR biomarker technology has the potential to deliver significant upside value for EKF shareholders. The Directors of Renalytix AI PLC are exploring funding options for that business, including equity funding. Existing EKF shareholders would have a continuing interest in the Renalytix AI business and the opportunity to participate in any separate equity funding of Renalytix AI PLC.


Key highlights of the Agreement

  • sTNFR biomarkers and AI technology deployed against de-identified clinical data from Mount Sinai’s 3 million patient electronic data warehouse and 43,000 patient records from the BioMeTM BioBank repository1

  • First pre-market approved product expected to launch in the US in H1 2019 for improved disease detection / care management, with the intention of gaining Food and Drug Administration (“FDA”) approval in 2020

  • Kidney disease affects an estimated 120 million people in the US and EU (c. 12% of the population), with 90% of these unaware they are at risk

  • $98bn in costs to Medicare attributed to preventable chronic kidney disease and dialysis annually


Under the Agreement, Mount Sinai will be able to use EKF’s sTNFR biomarkers alongside artificial intelligence (“AI”) technology to mine patient data and quickly identify which candidates are at the highest risk of progressive Diabetic Kidney Disease (“DKD”) potentially leading to End Stage Renal Disease (“ESRD”), a disease which costs the US healthcare system nearly $100 billion annually.


Mount Sinai is one of the largest integrated healthcare systems in the US, caring for diabetics and patients of African ancestry, the two major population groups most affected by kidney disease and dialysis. As part of the agreement, Renalytix AI PLC will look to leverage de-identified clinical data from Mount Sinai’s substantial data warehouse containing over 3,000,000 patient health records and its 43,000 patient BioMeTMBioBank repository to create an advanced learning system to monitor and flag patients at risk for kidney disease and unplanned “crashes” requiring costly dialysis treatment.


Plans for Renalytix AI

Subject to funding, the first product is expected to launch in H1 2019, targeting the significant costs to the US Medicare system of preventable dialysis and chronic kidney disease. Additional major US based healthcare systems are also expected to participate in clinical utility data collection and commercial launch. 


Upon successful completion of clinical validation in late 2018, Mount Sinai has agreed to participate in testing several thousand at-risk patients in an Institutional Review Board-approved clinical utility study in 2019, at an estimated cost of $6 million.  Renalytix AI will prepare its initial AI applications for FDA review and expanded validation through collaborations with leading academic medical centres, pharmaceutical and patient advocacy organisations in the United States and Europe with work planned to begin this year, aiming for FDA approval in 2020.


Barbara Murphy, MD, Dean for Clinical Integration and Population Health and Chair of the Department of Medicine at the Icahn School of Medicine at Mount Sinai, and Chair of the Renalytix AI Scientific Advisory Board said: 

“Our ability to apply the power of artificial intelligence against such a deep repository of data and disease specific biomarkers has the potential to change the game for all of our diabetic patients and other populations at risk for kidney disease.”


Julian Baines, Chief Executive Officer of EKF and Executive Chairman of Renalytix AI, added: 

“This is a significant partnership for Renalytix AI with one of the largest hospital groups in the United States. Coupling its technology with the Mount Sinai patient database will improve patient care in End Stage Renal Disease, a significant unmet medical need. The fact that so many patients on dialysis have never seen a specialist has to change, both from a patient care and cost perspective. I believe that this partnership will result in Renalytix AI being leaders in the field of kidney care, alongside Mount Sinai.” 


(1) The BioMe biobank is an electronic medical record (EMR)-linked biobank that enables researchers to conduct genetic, epidemiologic, molecular, and genomic studies quickly and efficiently on large collections of research specimens linked with medical information.



EKF Diagnostics Holdings plc
Julian Baines, CEO
Richard Evans, Finance Director and COO
00 44 29 2071 0570
N+1 Singer
Alex Price / Shaun Dobson
00 44 20 7496 3000

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

00 44 20 7933 8780 or ekf@walbrookpr.com
00 44 7980 541 893
00 44 7584 391 303